Valuation
- Market cap
- 1,410,000
- Revenue TTM
- $1,400,000
- Net income TTM
- $-2,910,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -207.86%
- Debt to equity
- 0.00
Trading
- Volume
- 2,000
- Avg volume
- 8,588
- Day's range
- $0.40 – $0.40
- Shares out
- 3,295,000
- Stochastic %K
- 36%
- Beta
- -0.23
- Analysts
- —
- Price target
- $8.00
Company profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in B...
Show more
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 781 652 4500
- Website
- https://avenuetx.com
- Address
- 1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
Latest news
No headlines yet.
